COVID-19 Update

In line with international standards to provide you with the safest environment, we have introduced the following additional precautionary measures at our facilities:

  • Limiting the number of people within our facilities to ensure physical distancing can be maintained.
  • Restricting access to patients with scheduled appointments only.
  • Restricting accompanying adults to only one person.
  • In the case of children under 12, allowing access only to those with a scheduled medical appointment.

Learn more about ICLDC’s Commitment to Safe Healthcare

Advanced Diabetes Conference

Programme

  • Day 1: 08/11/2021
  • Session 1 –Plenary:
  • 5:00 PM Recent Guidelines from ADA and EASD – Prof Maha Barakat – Research Director Imperial College London Diabetes Centre
  • 5:45 PMSensor technologies in Type 2 DM – Dr Ahmed El Laboudi – Consultant Endocrinologist, Imperial College London Diabetes Centre
  • 6:30 PM

    break

  • Session 2 –Diabetes throughout the lifespan:
  • 6:45 PMGenetics of Neonatal Diabetes – Dr Sara Suliman, Consultant Endocrinologist, Imperial College London Diabetes Centre
  • 7:15 PMPsychological problems in Adolescent patients with Diabetes – Dr Sawsan Halawi, Clinical Psychologist, Imperial College London Diabetes Centre
  • 7:45 PMDiabetes in Elderly populations - Dr Raad Nari, Internal Medicine Consultant, Imperial College London Diabetes Centre
  • Day 2:09/11/2021
  • Session 3 –Vasculature and Diabetes
  • 5:00 PMDiabetic Foot Disease – Faisal Hasan, Consultant Cardiologist, Cleveland Clinic Abu Dhabi
  • 5:30 PMSGLT-2 Inhibitors in heart failure - Dr Hani Sabbour – Consultant Cardiologist, Imperial College London Diabetes Centre
  • 6:00 PMBiomarkers for heart failure – Dr Jim Januzzi, Consultant Cardiologist, Massachusetts General Hospital.
  • Session 4 –New Treatments for diabetes
  • 6:45 PMSensor augmented pumps/Artificial Pancreas – Dr Lina Yassine- Consultant Endocrinologist, Imperial College London Diabetes Centre
  • 7:15 PMCombined GLP-1+ GIP agonist – Dr Tamer Coskun -Medical Fellow at Eli Lilly and Company
  • 7:45 PMOral semaglutide: A PIONEERing new treatment for type 2 diabetes Prof Richard Holt, Professor in Diabetes and Endocrinology, University of Southampton
  • 8:15 PMClose
Start Chat